Subscribe
13 June 2024NewsBig PharmaLiz Hockley

Foley Hoag strengthens biotech team with Fenwick & West patent expert

New counsel previously worked in-house at major pharmaceutical firm | Ex-Fenwick & West attorney has advised clients in areas including gene editing and antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
Former Novartis attorney takes patent expertise to Foley Hoag
16 May 2024   Firm adds counsel to IP department in Boston office | Ex-senior patent attorney at Novartis brings broad range of life sciences experience.
Biotechnology
Foley Hoag completes IP team hire
19 October 2023   Amy Baker Mandragouras’ (pictured) team follow her from Cooley | New counsel’s scientific expertise is “second-to-none” | Team has experience in strategic counselling and biotech patent portfolios.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders